You are here

Home » Content

COMPARATIVE STUDY ON THE PREPARATION AND CHARACTERIZATION OF INCLUSION COMPLEXES OF BCS CLASS II DRUG WITH CYCLODEXTRINS

Journal Name:

  • Advance Research in Pharmaceuticals and Biologicals

Publication Year:

  • 2013

Key Words:

Author NameUniversity of Author
Abstract (2. Language): 
Fenofibrate (FFB) is an effective lipid regulating agent. Chemically it is 2-[4-(4-chloro benzoyl]-2 methyl propanoic acid, 1-methyl ethyl ester. It belongs to BCS class II and require enhancement in solubility and dissolution rate for increasing its oral bioavailability. In the present work, β- Cyclodextrin (β-CD) and Hydroxy Propyl β- Cyclodextrin (HP β-CD) complexes of FFB were prepared and evaluated for solubility and dissolution rate .The aqueous solubility was increased linearly as a function of the concentration of cyclodextrins. Physical characterization of solid inclusion complexes of FFB was studied by DSC and IR. An increase of 21 and 30 fold in the dissolution rate of FFB was observed with FFB- β-CD (1:3) - F6 and FFB- HP β-CD (1:3) - F12 prepared by kneading method respectively. The increase in the dissolution rate of the drug may be due to increase of wettability, the hydrophilic nature of carriers and also due to possibility of reduction in drug crystallinity.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon 179107_rani_et_al.pdf
  • 2
420-425
  • English

REFERENCES

References: 

1. The Merck Index, 14th Edn., Merck Research
Laboratories, Division of Merck & Co, Inc.
Whitehouse Station NJ USA, pp-679.
2. Martindale, The Complete Drug Reference, 36th
Edition. The Pharmaceutical Press, London, 2009,
pp-1286.
3. A. Ajmera, S. Deshpande, S. Kharadi, K. Rathod, K.
Patel and P. Patel. Dissolution rate enhancement of
atorvastatin, fenofibrate and ezetimibe by inclusion
complex with β-cyclodextrin, Asian J Pharm Clin
Res, 5(4):73-76 (2012).
4. G. Boden, C. Homko, M. Mozzoli, M. Zhang, K. Kresge,
and P. Cheung. Combined Use of Rosiglitazone and
Fenofibrate in Patients With Type 2 Diabetes
Prevention of Fluid Retention Diabetes, 56: 248-255
(2007).
5. R. Kumar, S. Patil, M. B. Patil, S. R. Patil, M. S.
Paschapur. Formulation and Evaluation of Mouth
Dissolving Tablets of Fenofibrate Using Sublimation
Technique, Int. J. Chem Tech Res. 1(4): 840-850
(2009).
6. E. M. M. D. Valle. Cyclodextrins and their uses: a
review Process Biochemistry, Xxx: xxx–xx (2003).
7. K. Gowthamarajan, S. K. Singh. Dissolution Testing
for Poorly Soluble Drugs: A Continuing Perspective,
Dissolution Technologies 24-33 (2010).
8. A. Magnusdottir, M. Masson, T. Loftsson. J. Incl.
Phenom. Macroc. Chem. 44: 213-218 (2002).
9. T. Patel, L. D. Patel, T. Patel, S. Makwana, T. Patel.
Enhancement of dissolution of Fenofibrate by Solid
dispersion Technique, Int. J. Res. Pharm. Sci. 1 (2):
127-132 (2010).
10. C. Nicolescu, C. Arama, A. Nedelcu, C. M. Monciu.
Phase solubility studies of the inclusion complexes
of repaglinide with β-cyclodextrin and β-
cyclodextrin derivatives, Farmacia, 58(5): 620-628
(2010).
11. V. N. V. Vinay, K. Venkatesh, K. Phanindra, S. Keerthi
and K. Swetha. Formulation and evaluation of solid
dispersions of fenofibrate for dissolution rate
enhancement, Journal of Chemical and
Pharmaceutical Research 4(11): 4752-4756 (2012).
12. V. R. Sinha, R. Anitha, S. Ghosh, A. Rachana Kumria, J.
Rajaram Bhinge, M. Kumar. Physicochemical
characterization and in vitro dissolution behaviour
of celecoxib--cyclodextrin inclusion complexes, Acta
Pharm. 57: 47–60 (2007).

Thank you for copying data from http://www.arastirmax.com